

**RABCONNECTIN-3-BINDING PROTEIN**

The present application claims priority to Japanese Application No. 2002-319521, filed on November 1, 2002, which is incorporated herein by reference.

**BACKGROUND OF THE INVENTION**

The present invention relates to a protein binding rabconnectin-3 and a GDP/GTP exchange protein, and a polynucleotide encoding the same.

Rab3A is a member of a Rab3 family consisting of four members: Rab3A, Rab3B, Rab3C, and Rab3D, and Rab3A is known to play a key regulatory role in  $\text{Ca}^{2+}$ -dependent exocytosis of neurotransmitters. The process of the  $\text{Ca}^{2+}$ -dependent exocytosis of neurotransmitters includes the following steps: (1) translocation of synaptic vesicles from the reserve pool to the active zone of the presynaptic plasma membrane where a  $\text{Ca}^{2+}$  channel localizes, (2) docking of the vesicles to the active zone, (3) transition from the docking to the priming of the vesicles in the readily releasable pool, and (4) fusion of the vesicles with the membrane induced by  $\text{Ca}^{2+}$  influx.

The analysis of Rab3A gene knockout mouse has revealed two actions of Rab3A: (1) it facilitates the translocation and docking of synaptic vesicles to the presynaptic plasma membrane, and (2) it prevents  $\text{Ca}^{2+}$ -triggered fusion of the vesicles with the plasma membrane. However, the molecular mechanism of these actions of Rab3A in the  $\text{Ca}^{2+}$ -dependent exocytosis of neurotransmitters is

not known.

The Rab3 family members are regulated by three regulators: a GDP dissociation inhibitor (Rab GDI), a GDP/GTP exchange protein (Rab3 GEP), and a GTPase-activating protein (Rab3 GAP). Rab3 GEP and Rab3 GAP are specific for the Rab3 family members, but Rab GDI is active on all the Rab family members. The cyclical activation and inactivation of Rab3A by the action of these regulators are essential for the action of Rab3A in  $\text{Ca}^{2+}$ -dependent exocytosis of neurotransmitters. For example, a current model for the mode of action of these regulators is as follows: GDP-Rab3A is kept in the cytosol as a complex with Rab GDI. This complex is recruited to synaptic vesicles where GDP-Rab3A is activated to GTP-Rab3A by the action of Rab3 GEP with the help of another unidentified molecule, such as GDI displacement factor (GDF) for Rab5, Rab7, and Rab9, or Rab recycling factor (RRF) for Ypt1 and Ypt7. Neither GDF nor RRF has been isolated. GTP-Rab3A binds its two downstream effectors: rabphilin-3 and Rim-3 localized on the vesicles and the active zone, respectively. Before or after the fusion step, GTP-Rab3A in a complex with the effectors is inactivated to GDP-Rab3A by the action of Rab3 GAP. GDP-Rab3A is trapped by Rab GDI, resulting in the translocation from the vesicles to the cytosol. Thus, it is presumed that Rab3 GEP and Rab3 GAP are recruited to the vesicles when they function; however, their mechanisms remain unknown.

Recently, a novel protein was isolated from a crude synaptic vesicle (CSV) fraction of rat brain by

coimmunoprecipitation with Rab3 GEP or Rab3 GAP, and was  
named rabconnectin-3 (see The Journal of Biological  
Chemistry, 2002, Vol. 277, No. 12, PP. 9629-9632). Human  
rabconnectin-3 consists of 3,036 amino acids and shows a  
5 calculated molecular weight of 339,753. Rabconnectin-3 has  
12 WD domains. Rabconnectin-3 is abundantly expressed in  
the brain where it is associated with the synaptic vesicles.  
Moreover, it has been found that further two proteins are  
coimmunoprecipitated with Rab3 GEP from a CSV fraction of  
10 rat brain (see The Journal of Biological Chemistry, 2002,  
Vol. 277, No. 12, PP. 9629-9632).

#### SUMMARY OF THE INVENTION

In one aspect, the invention provides protein useful  
15 for clarifying the regulation mechanism of  $\text{Ca}^{2+}$ -dependent  
exocytosis (in particular, the activation and inactivation  
of Rab3A. In another aspect, the invention provides a  
method of screening a material useful for regulating  $\text{Ca}^{2+}$ -  
dependent exocytosis (in particular, the activation and  
20 inactivation of Rab3A), using the above protein.

The inventors of the present invention have succeeded  
in obtaining a rabconnectin-3-binding protein that directly  
binds a GDP/GTP exchange protein.

In certain embodiments the present invention provides  
25 the following.

(1) A protein as defined in (a) or (b):

(a) a protein having the amino acid sequence of SEQ  
ID NO: 2; and

(b) a protein having the amino acid sequence of SEQ

ID NO: 2 with one or several amino acids deleted, replaced, or added, and having an activity of binding rabconnectin-3 and a GDP/GTP exchange protein.

(2) A protein according to item (1) which has the  
5 amino acid sequence of SEQ ID NO: 2.

(3) A polynucleotide that encodes the protein as defined in item (1) or (2).

(4) A polynucleotide according to item (3), having a nucleotide sequence of nucleotide numbers 1 to 4470 of a  
10 nucleotide sequence of SEQ ID NO: 1.

(5) A polynucleotide as defined in (a) or (b):

(a) a polynucleotide having a nucleotide sequence of nucleotide numbers 1 to 4470 of a nucleotide sequence of SEQ ID NO: 1; and

15 (b) a polynucleotide which hybridizes with the polynucleotide having a nucleotide sequence that is complementary to the nucleotide sequence of nucleotide numbers 1 to 4470 of the nucleotide sequence of SEQ ID NO: 1 under a stringent condition, and encodes a protein having  
20 an activity of binding rabconnectin-3 and a GDP/GTP exchange protein.

(6) A polynucleotide as defined in (a) or (b):

(a) a polynucleotide having a nucleotide sequence of nucleotide numbers 1 to 4470 of a nucleotide sequence of  
25 SEQ ID NO: 1; and

(b) a polynucleotide having a nucleotide sequence whose homology to the nucleotide sequence of nucleotide numbers 1 to 4470 of the nucleotide sequence of SEQ ID NO: 1 is 80% or higher, and encoding a protein having an

activity of binding rabconnectin-3 and a GDP/GTP exchange protein.

(7) A recombinant vector including the polynucleotide as defined in any one of items (3) to (6).

5 (8) A transformant obtained by transforming a host with the polynucleotide as defined in any one of items (3) to (6).

(9) A method of producing a protein having an activity of binding rabconnectin-3 and a GDP/GTP exchange  
10 protein, comprising:

culturing the transformant as defined in item (8) in a culture; and

collecting, from the culture, a protein having the activity of binding rabconnectin-3 and the GDP/GTP exchange  
15 protein.

(10) A use of a probe or a primer including a polynucleotide having at least 15 nucleotides complementary to the polynucleotide as defined in any one of items (3) to (6), which is adapted to detect the polynucleotide as  
20 defined in any one of items (3) to (6).

(11) A method of analyzing a first polynucleotide as defined in any one of items (3) to (6), comprising hybridizing a probe or a primer with the first polynucleotide, wherein the probe or primer includes a  
25 second polynucleotide having at least 15 nucleotides complementary to the first polynucleotide.

(12) An analyzing method according to item (11), wherein the first polynucleotide is present in a tissue or a cell.

(13) A method of analyzing a first polynucleotide encoding the protein as defined in item (1) or (2), comprising hybridizing a probe or a primer with the first polynucleotide, wherein the probe or primer includes a  
5 second polynucleotide having at least 15 nucleotides complementary to the first polynucleotide.

(14) A method of analyzing a gene according to item (13), wherein the first polynucleotide is present in a tissue or a cell.

10 (15) A method comprising amplifying an mRNA in a tissue or a cell by an RT-PCR method with a primer that includes a polynucleotide having at least 15 nucleotides complementary to the polynucleotide as defined in any one of items (3) to (6).

15 (16) An antisense polynucleotide which hybridizes with an mRNA encoding the protein as defined in item (1) or (2).

(17) A ribozyme for cutting an mRNA encoding the protein as defined in item (1) or (2).

20 (18) A double-stranded RNA for cutting an mRNA encoding the protein as defined in item (1) or (2) by RNA interference.

(19) An antibody against the protein as defined in item (1) or (2).

25 (20) A method of immunohistologically analyzing the protein as defined in item (1) or (2), comprising contacting the protein with an antibody as defined in item (19).

(21) An analyzing method according to item (20),

further comprising determining the location of the a protein.

(22) An analyzing method according to item (20), further comprising determining the amount of expression of the protein.

(23) A method of screening for a material that promotes or inhibits binding between a protein as defined in item (1) or (2) or a heterogeneous homologous protein thereof, and rabconnectin-3, comprising contacting the protein with rabconnectin-3 in the presence and absence of candidate materials, and selecting a material which increases or decreases the binding.

(24) A method of screening for a material that promotes or inhibits binding between a protein as defined in item (1) or (2) or a heterogeneous homologous protein thereof, and a Rab 3 GDP/GTP exchange protein, comprising contacting the protein with the Rab3 GDP/GTP exchange protein in the presence and absence of candidate materials, and selecting a material which increases or decreases the binding.

In other embodiments, the present invention provides a protein useful for clarifying the regulation mechanism of  $\text{Ca}^{2+}$ -dependent exocytosis (in particular, the activation and inactivation of Rab3A). In yet other embodiments, the present invention provides a method of screening for a material useful for regulating  $\text{Ca}^{2+}$ -dependent exocytosis (in particular, the activation and inactivation of Rab3A), using the above protein.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 shows isolation and a primary structure of p160 (rabconnectin-3 $\beta$ ). (A) Results (electrophoresis photograph) of coimmunoprecipitation of p160 (rabconnectin-3 $\beta$ ) with an anti-Rab3 GEP antibody. 1, p340; 2, p200; 3, p160; and 4, p60. (B) A schematic structure, wherein gray boxes represent WD domains. (C) Results (electrophoresis photograph) of Western blotting of recombinant rabconnectin-3 $\beta$ . Lane 1, HEK293 cells (1  $\mu$ g of protein); lane 2, pCMVFa rabconnectin-3 $\beta$ -transfected HEK293 cells (1  $\mu$ g of protein); and lane 3, homogenate of rat brain (20  $\mu$ g of protein).

Fig. 2 shows tissue and subcellular distributions of rabconnectin-3 $\beta$ . (A) Tissue distribution of rabconnectin-3 $\beta$  (electrophoresis photograph); and (B) subcellular distribution of rabconnectin-3 $\beta$  (electrophoresis photograph). Rc-3 $\beta$ , rabconnectin-3 $\beta$ ; Rc-3 $\alpha$ , rabconnectin-3 $\alpha$ ; GEP, Rab3 GEP; Ho, homogenate fraction; P1, nuclear pellet fraction; P2, crude synaptosome fraction; P3, microsome fraction; S, soluble cytosol fraction; P2A, myelin fraction; P2B, endoplasmic reticulum and Golgi complex fraction; P2C, synaptosome fraction; P2D, mitochondria fraction; SS, synaptic soluble fraction; CSV, crude synaptic vesicle fraction; and CSM, crude synaptic membrane fraction.

Fig. 3 shows immunofluorescent microscope images (microscope photographs) showing the coexistence of rabconnectin-3 $\alpha$  and -3 $\beta$  in synapses.

Fig. 4 shows results of Western blotting illustrating



the direct binding of Rab3 GEP and indirect binding of Rab3 GAP to rabconnectin-3 $\beta$  (electrophoresis photographs).

#### DETAILED DESCRIPTION OF THE INVENTION

5 <Protein, etc. of the present invention>

The protein of the present invention directly binds rabconnectin-3 and Rab3 GEP. The protein of the present invention forms a complex with rabconnectin-3. Therefore, hereinafter, the protein of the present invention will be also referred to as rabconnectin-3 $\beta$ , and rabconnectin-3 will be referred to as rabconnectin-3 $\alpha$ .

Among the proteins of the present invention, the protein having an amino acid sequence of SEQ ID NO: 2 is a protein identified as human rabconnectin-3 $\beta$ , as described in the examples shown later. With respect to a protein, existence of a mutant having the same function is expected. Furthermore, by appropriately altering (for example, conservatively replacing) an amino acid sequence of a protein, a mutant having the same function can be obtained. Therefore, proteins having an amino acid sequence of SEQ ID NO: 2 with one or several amino acids deleted, replaced, or added and having an activity of binding rabconnectin-3 and a GDP/GTP exchange protein are also included in the protein of the present invention.

25 An amino acid sequence of a protein may be altered by altering a nucleotide sequence of a polynucleotide encoding the protein by well-known means such as a site-directed mutagenesis, and expressing the polynucleotide having the altered nucleotide sequence. Furthermore, the activity of

binding rabconnectin-3 and a GDP/GTP exchange protein means binding them under a physiological condition, and this activity can be measured in accordance with a known method of measuring the binding between proteins (for example, see  
5 examples shown later, or "Protein Experiment Protocol Function Analysis", Shujunsha (1997), Chapter 9, Immunoprecipitation, Interaction Analysis Using Affinity Resin, pp. 151-161). Thus, it would be easy for those skilled in the art to determine whether or not a mutant has  
10 the same function.

An amino acid residue constituting the protein of the present invention may be a naturally occurring residue or a modified residue. Examples of the modification of an amino acid residue include acylation, acetylation, amidation,  
15 arginylation, GPI anchor formation, cross-linking,  $\gamma$ -carboxylation, cyclization, formation of a covalent cross-linkage, glycosylation, oxidation, covalent binding of a lipid or a fat derivative, formation of a disulfide bond, selenoylation, demethylation, decomposition of a  
20 protein, covalent binding of a nucleotide or a nucleotide derivative, hydroxylation, formation of pyroglutamate, covalent binding of flavin, prenylation, covalent binding of a heme moiety, covalent binding of phosphatidylinositol, formylation, myristoylation, methylation, ubiquitination,  
25 iodination, racemization, ADP-ribosylation, sulfation, phosphorylation, etc. Furthermore, the protein of the present invention includes a precursor with a signal peptide portion, a mature protein lacking in a signal peptide portion, and a fusion protein modified by another

peptide sequence. As the peptide sequence to be added to the protein of the present invention, a sequence (a vector such as pcDNA3.1/Myc-His(Invitrogen) can be used) facilitating the purification of a protein such as an  
5 influenza agglutinin (HA), glutathione S transferase (GST), substance P, poly histidine tag (6 × His, 10 × His, etc.), protein C fragment, maltose binding protein (MBP), immunoglobulin constant region,  $\alpha$ -tubulin fragment,  $\beta$ -galactosidase, B-tag, c-myc fragment, E-tag (an epitope  
10 on a monoclonal phage), FLAG (Hopp et al. (1988) Bio/Technol. 6: 1204-10), lck tag, p18 HIV fragment, HSV-tag (a human herpes simplex virus glycoprotein), SV40T antigen fragment, T7-tag (T7 gene 10 protein), VSV-GP fragment (Vesicular stomatitis virus glycoprotein), etc., a  
15 sequence providing stability when a protein is produced by a recombinant technique, and the like can be selected.

The protein of the present invention can be produced by a known gene recombinant technique or a chemical synthesis method. In the case of producing the protein of  
20 the present invention by a gene recombinant technique, the protein to be produced may or may not be glycosylated and may further have different molecular weights, isoelectric points, etc., depending upon the kind of a host to be selected. Usually, in the case where the protein is  
25 expressed using a prokaryotic cell such as *E. coli* as a host, the protein to be obtained is produced with a methionine residue added to an N-terminus originally owned by the protein. The proteins having different structures due to the use of different hosts are also included in the

protein of the present invention.

<Production of a protein>

In the case of producing a protein *in vitro*, the  
5 protein can be produced in an *in vitro* system containing no  
cell in accordance with a method of *in vitro* translation  
(Dasso and Jackson (1989) Nucleic Acids Res. 17: 3129-44),  
etc. In contrast, in the case of producing a protein using  
cells, first, an appropriate host cell is selected, and  
10 transformed with an intended DNA. Then, the transformed  
cells are cultured, whereby a desired protein can be  
obtained. Culture is performed by a known method suitable  
for the selected cell. For example, in the case of  
selecting animal cells, a medium such as DMEM (Virology 8:  
15 396 (1959)), MEM (Science 122: 501 (1952)), RPMI 1640 (J.  
Am. Med. Assoc. 199: 519 (1967)), 199 (Proc. Soc. Biol. Med.  
73: 1 (1950)), IMDM, etc. is used with supplementation of a  
serum such as fetal calf serum (FCS), if required, and  
cultivation can be performed at pH of about 6 to 8 and at  
20 30°C to 40°C for about 15 to 200 hours. In addition, if  
required, the medium can be exchanged in the course of  
culture, and aeration and stirring can be performed.

On the other hand, in order to establish an *in vivo*  
production system of a protein, an intended DNA is  
25 transduced to an animal or a plant, and a protein is  
produced *in vivo*. An animal system such as mammals (e.g.,  
goat, pig, sheep, mouse, bovine, etc.), insects (e.g.,  
silkworm) (Susumu (1985) Nature 315: 592-4), and the like  
are known (Lubon (1998) Biotechnol. Annu. Rev. 4: 1-54).

Furthermore, a transgenic animal can also be used in a mammal system.

For example, in the case of allowing a desired protein to be secreted to milk of a goat, a DNA encoding the protein is bound to a DNA encoding a protein that is specifically secreted in milk such as  $\beta$ -casein, and the intended protein is expressed as a fusion protein. Then, the DNA encoding the fusion protein is transduced to the embryo of a goat. The DNA-transduced embryo is transplanted to the uterus of a female goat. A transgenic goat from the female goat or its offspring secretes a desired protein in milk. In order to increase the amount of milk, if required, hormones can be administered (Ebert et al. (1994) Bio/Technology 12: 699-702).

A protein-producing system of a transgenic plant using a plant such as tobacco is known. First, a DNA encoding a desired protein is integrated to a vector suitable for expression in a plant such as pMON530, and transduced to a bacterium such as *Agrobacterium tumefaciens*. A plant such as *Nicotina tabacum* is infected with the DNA-transduced bacterium to regenerate a plant, whereby the desired protein can be isolated from a leaf of the transgenic plant thus obtained (Julian et al. (1994) Eur. J. Immunol. 24: 131-8). Other methods have also been established: a method of transducing a DNA to a protoplast using PEG to regenerate a plant body (Gene Transfer to Plants, Potrykus and Spangenberg ed. (1995) pp. 66-74; suitable for indica rice); a method of transducing a DNA to a protoplast with an electric pulse to regenerate a plant

body (Toki et al. (1992) Plant Physiol. 100: 1503-7; suitable for japonica rice); a method of transducing a DNA directly to a plant cell by a particle gun method to regenerate a plant body (Christou et al. (1991)

5 Bio/Technology 9: 957-62); a method of transducing a DNA to a cell via *Agrobacterium* to regenerate a plant body (Hiei et al. (1994) Plant J. 6: 271-82), etc. Regarding the method of regenerating a plant, Toki et al. (1995) Plant Physiol. 100: 1503-7 can be referred to.

10       Once a transgenic plant is obtained, a plant host producing the protein of the present invention can be propagated similarly by using, as a material, a seed, a fruit, a tuber, a tuberous root, a root, a cut spike, a callus, a protoplast, or the like.

15       Usually, regarding the protein of the present invention produced by a gene recombinant technique, first, in the case where the protein is secreted extracellularly, a medium is collected, particularly, in the case of a transgenic organism, a body fluid, etc. is collected, and  
20 in the case where the protein is produced intracellularly, a lysate obtained by lysing the cells is collected. Then, as a method of purifying the protein, by appropriately combining known salting-out, distillation, various kinds of chromatography, gel electrophoresis, gel filtration,  
25 ultrafiltration, recrystallization, acid extraction, dialysis, immunoprecipitation, solvent precipitation, solvent extraction, ammonium sulfate or ethanol precipitation, etc., a desired protein is purified. As the chromatography, ion exchange such as anion or cation

exchange, affinity, reversed phase, adsorption, gel filtration, hydrophobic, hydroxyapatite, phosphocellulose, lectin chromatography, and the like are known (Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Marshak et al. ed., Cold Spring Harbor Laboratory Press (1996)). Liquid phase chromatography such as HPLC or FPLC can be used.

Furthermore, a naturally occurring protein may be purified. For example, a protein can be purified by affinity chromatography, using an antibody to the protein of the present invention (described later) (Current Protocols in Molecular Biology, John Wiley & Sons (1987) Section 16.1-16.19). Furthermore, a purification method can also be used which uses a glutathione column in the case of a fusion protein with GST and uses a nickel column in the case of a fusion protein with histidine tag added thereto. In the case of producing the protein of the present invention as a fusion protein, after purification, thrombin, factor Xa, or the like can be used to cut an unnecessary portion, if required. Furthermore, if required, the obtained polypeptide can be modified with an enzyme such as chymotrypsin, glucosidase, trypsin, protein kinase, lysyl endopeptidase, or the like.

## <Polynucleotide>

The polynucleotide of the present invention encodes the protein of the present invention. This polynucleotide can be used when the protein of the present invention is expressed with a genetic engineering technique.

Furthermore, the polynucleotide of the present invention can be used as a detection reagent of a rabconnectin-3-binding protein gene. That is, a molecular biological analysis can be performed, using a polynucleotide encoding  
5 the protein of the present invention or a partial specific fragment thereof, and a method of detecting a polynucleotide and a method of analyzing the amount of expression of the polynucleotide are provided. Examples of such methods include Southern blotting, Northern blotting,  
10 PCR, RT-PCR, quantitative RT-PCR, *in situ* hybridization, and the like.

In the present invention, it is confirmed that the rabconnectin-3-binding protein localizes in a synapse, so that the rabconnectin-3-binding protein can be used as a  
15 marker of a synapse. More specifically, a synapse can be detected by detecting the expression of a rabconnectin-3-binding protein gene, using a polynucleotide encoding the protein of the present invention or a partial specific fragment thereof. Thus, the polynucleotide of the present  
20 invention can be used as a synapse detection reagent. Furthermore, it is confirmed that the protein of the present invention binds rabconnectin-3 and a GDP/GTP exchange protein, so that the polynucleotide of the present invention can also be used for detecting rabconnectin-3 and  
25 the GDP/GTP exchange protein.

The term "polynucleotide" as used herein refers to a polymer composed of a plurality of bases or base pairs such as deoxyribonucleic acids (DNA) or ribonucleic acids (RNA), and includes a cDNA, a genomic DNA, chemically synthesized



DNA, and RNA. The term "polynucleotide" also includes polynucleotides containing, if required, bases other than naturally occurring bases, such as 4-acetylcytidine, 5-(carboxyhydroxymethyl)uridine, 2'-O-methylcytidine, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluridine, dihydrouridine, 2'-O-methylpseudouridine,  $\beta$ -D-galactosylqueuosine, 2'-O-methylguanosine, inosine, N6-isopentenyladenosine, 1-methyladenosine, 1-methylpseudouridine, 1-methylguanosine, 1-methylinosine, 2,2-dimethylguanosine, 2-methyladenosine, 2-methylguanosine, 3-methylcytidine, 5-methylcytidine, N6-methyladenosine, 7-methylguanosine, 5-methylaminomethyluridine, 5-methoxyaminomethyl-2-thiouridine,  $\beta$ -D-mannosylqueuosine, 5-methoxycarbonylmethyl-2-thiouridine, 5-methoxycarbonylmethyluridine, 5-methoxyuridine, 2-methylthio-N6-isopentenyladenosine, N-((9- $\beta$ -D-ribofuranosyl-2-methylthiopurin-6-yl)carbamoyl)threonine, N-((9- $\beta$ -D-ribofuranosylpurin-6-yl)-N-methylcarbamoyl)-threonine, uridine-5-oxyacetic acid-methyl ester, uridine-5-oxyacetic acid, wybutosine, pseudouridine, queuosine, 2-thiocytidine, 5-methyl-2-thiouridine, 2-thiouridine, 4-thiouridine, 5-methyluridine, N-((9- $\beta$ -D-ribofuranosylpurin-6-yl)carbamoyl)threonine, 2'-O-methyl-5-methyluridine, 2'-O-methyluridine, wybutosine, 3-(3-amino-3-carboxypropyl)uridine, and the like.

Examples of the polynucleotide of the present invention include a polynucleotide having a nucleotide sequence of nucleotide numbers 1-4470 of the nucleotide

sequence of SEQ ID NO: 1. The nucleotide sequence of this polynucleotide is determined in the subsequent example. Furthermore, the polynucleotide of the present invention includes a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 2 encoding the rabconnectin-3 $\beta$  protein, or a sequence complementary to the nucleic acid sequence. The nucleic acid sequence encoding such an amino acid sequence includes a nucleic acid sequence different from the sequence of SEQ ID NO: 1 due to the degeneracy of a genetic code, in addition to the nucleic acid sequence of SEQ ID NO: 1. In the case of using the polynucleotide of the present invention for expressing a polypeptide by a genetic engineering technique, a nucleotide sequence with a high expression efficiency can be selected and designed, by taking into consideration the codon usage frequency in a host to be used (Grantham et al. (1981) Nucleic Acids Res. 9: 43-74).

The polynucleotide of the present invention includes a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 2 with one or several amino acids deleted, integrated, replaced, or added, and encoding the rabconnectin-3 $\beta$  protein or its antigenic fragment, or a sequence complementary to the nucleic acid sequence. It is known that, in a mutant polypeptide composed of an amino acid sequence with one or several amino acids deleted, integrated, replaced, or added, the same biological activity as that of the original polypeptide is maintained (Mark et al. (1984) Proc. Natl. Acad. Sci. USA 81: 5662-6; Zoller and Smith (1982) Nucleic Acids Res. 10: 6487-500;

Wang et al. (1984) Science 224: 1431-3; Dalbadie-McFarland et al. (1982) Proc. Natl. Acad. Sci. USA 79: 6409-13). The several amino acids are generally 2 to 30, preferably 2 to 20, more preferably 2 to 10, and particularly preferably 2 to 5 amino acids.

Herein, the replacement of an amino acid denotes a mutation in which one and more amino acid residue in a sequence is replaced by a different kind of amino acid residue. In the case where an amino acid sequence encoded with the polynucleotide of the present invention is altered by such replacement, when it is necessary to retain the function of a protein, it is preferable to perform conservative replacement. Conservative replacement denotes changing a sequence so as to encode an amino acid having a similar property as that of an amino acid before replacement. Amino acids can be classified by their properties into, for example, nonpolar amino acids (Ala, Ile, Leu, Met, Phe, Pro, Trp, Val), uncharged amino acids (Asn, Cys, Gln, Gly, Ser, Thr, Tyr), acid amino acids (Asp, Glu), basic amino acids (Arg, His, Lys), neutral amino acids (Ala, Asn, Cys, Gln, Gly, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val), aliphatic amino acids (Ala, Gly), branched amino acids (Ile, Leu, Val), hydroxyamino acids (Ser, Thr), amide-type amino acids (Gln, Asn), sulfur-containing amino acids (Cys, Met), aromatic amino acids (His, Phe, Trp, Tyr), heterocyclic amino acids (His, Trp), imino acids (Pro, 4Hyp), and the like. Among them, replacement among Ala, Val, Leu, and Ile, between Ser and Thr, between Asp and Glu, between Asn and Gln, between Lys

and Arg, and between Phe and Tyr is preferable for retaining the property of a protein. There is no particular limit to the number and site of amino acids to be altered, as long as an amino acid encoded by the  
5 polynucleotide has antigenicity of the rabconnectin-3 $\beta$  protein.

The polynucleotide encoding the amino acid sequence of SEQ ID NO: 2 with one or several amino acids deleted, integrated, replaced, or added can be prepared in  
10 accordance with a method such as a site-directed mutagenesis or the like described in "Molecular Cloning, A Laboratory Manual 2nd ed." (Cold Spring Harbor Press (1989)), "Current Protocols in Molecular Biology" (John Wiley & Sons (1987-1997); in particular, Section 8.1-8.5),  
15 Hashimoto-Goto et al. (1995) Gene 152: 271-5, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82: 488-92, Kramer and Fritz (1987) Method. Enzymol. 154: 350-67, Kunkel (1988) Method. Enzymol. 85: 2763-6, and the like.

Furthermore, the polynucleotide of the present  
20 invention includes a nucleic acid sequence that hybridizes under a stringent condition to the nucleotide sequence of SEQ ID NO: 1 or a sequence complementary thereto and encodes the rabconnectin-3 $\beta$  protein or its antigenic fragment. As such a polynucleotide, an isoform, an  
25 alternative isoform, and an allelic mutant are conceived, and they are included in the polynucleotide of the present invention. Such a polynucleotide can be obtained from a cDNA library and a genome library of an animal such as a human being, a mouse, a rat, a rabbit, a hamster, a fowl, a

pig, a bovine, a goat, or a sheep by a known hybridization method such as colony hybridization, plaque hybridization, or Southern blotting, using a polynucleotide composed of a nucleic acid sequence including SEQ ID NO: 1 or its

5 fragment as a probe. Regarding a method of producing a cDNA library, "Molecular Cloning, A Laboratory Manual 2nd ed." (Cold Spring Harbor Press (1989)) can be referred to. Furthermore, commercially available cDNA libraries and genome libraries may be used.

10 More specifically, in production of a cDNA library, first, total RNA is prepared from cells, an organ, a tissue, or the like expressing the polynucleotide of the present invention, by a known method such as guanidine ultracentrifugation method (Chirwin et al. (1979) Biochemistry 18: 5294-9), or AGPC method (Chomczynski and Sacchi (1987) Anal. Biochem. 162: 156-9), and mRNA is purified using mRNA Purification Kit (Pharmacia) or the like. A kit for directly preparing mRNA such as a QuickPrep mRNA Purification Kit (Pharmacia) may also be  
15 used. Next, a cDNA is synthesized from the mRNA thus obtained, using a reverse transcriptase. A kit for cDNA synthesis such as an AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (Seikagaku Corporation) is also commercially available. As the other methods, a cDNA may  
20 be synthesized and amplified by a 5'-RACE method using PCR (Frohman et al. (1988) Proc. Natl. Acad. Sci. USA 85: 8998-9002; Belyavsky et al. (1989) Nucleic Acids Res. 17: 2919-32). Furthermore, in order to produce a cDNA library having a high full length ratio, a known method such as an

oligocap method (Maruyama and Sugano (1994) Gene 138: 171-4; Suzuki (1997) Gene 200: 149-56) or the like can be adopted. The cDNA obtained as described above is integrated to an appropriate vector.

5           The hybridization condition in the present invention is, for example, "2 × SSC, 0.1% SDS, 50°C", "2 × SSC, 0.1% SDS, 42°C", or "1 × SSC, 0.1% SDS, 37°C". A more stringent condition is, for example, "2 × SSC, 0.1% SDS, 65°C", "0.5 × SSC, 0.1% SDS, 42°C", "0.2 × SSC, 0.1% SDS, 65°C", and  
10 the like. More specifically, as a method using a Rapid-hyb buffer (Amersham Life Science), the following method can also be conceived. That is, prehybridization is performed at 68°C for 30 minutes or more. Thereafter, a probe is added and kept at 68°C for one hour or more to form a  
15 hybrid. Then, the hybrid is washed three times at room temperature for 20 minutes in 2 × SSC (0.1% SDS), washed three times at 37°C for 20 minutes in 1 × SSC (0.1% SDS), and finally washed twice at 50°C for 20 minutes in 1 × SSC (0.1% SDS). Alternatively, the following may also be  
20 performed. For example, prehybridization is performed at 55°C for 30 minutes or more in an Expresshyb Hybridization Solution (CLONTECH). A labeling probe is added. The mixture is incubated at 37°C to 55°C for one hour or more. Then, the hybrid is washed three times at room temperature  
25 for 20 minutes in 2 × SSD (0.1% SDS), and washed once at 37°C for 20 minutes in 1 × SSC (0.1% SDS). Herein, for example, by increasing the temperature in prehybridization, hybridization, and the second washing, more stringent conditions can be obtained. For example, the temperature

of prehybridization and hybridization can be set to be 60°C, and can be set to be 68°C as a more stringent condition. Alternatively, hybridization is performed at 42°C in 4 × SSC containing 0.1% SDS, and washing is performed at 25°C  
5 in 2 × SSC containing 0.1% SDS (preferably 50°C in 0.1 × SSC containing 0.1% SDS) for one hour. Those skilled in the art would appropriately set various conditions such as a probe concentration, a probe length, and a reaction time, in addition to the conditions such as a salt concentration  
10 and a temperature of a buffer.

Regarding the detailed procedures of a hybridization method, "Molecular Cloning, A Laboratory Manual 2nd ed." (Cold Spring Harbor Press (1989); particularly, Section 9.47-9.58), "Current Protocols in Molecular Biology" (John  
15 Wiley & Sons (1987-1997); particularly, Section 6.3-6.4), "DNA Cloning 1: Core Techniques, A Practical Approach 2nd ed." (Oxford University (1995); particularly, Section 2.10 regarding the conditions), etc. can be referred to. Examples of a polynucleotide to be hybridized include a  
20 polynucleotide containing a nucleic acid sequence having the identity of at least 50% or more, preferably 70%, more preferably 80%, and still more preferably 90% (e.g., 95% or more, further preferably 99%) with respect to the nucleic acid sequence containing SEQ ID. No: 1. Such identity can  
25 be determined in accordance with a BLAST algorithm (Altschul (1990) Proc. Natl. Acad. Sci. USA 87: 2264-8; Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-7). As a program based on this algorithm, BLASTX or the like has been developed as a program for determining

the identity regarding an amino acid sequence, BLASTN or the like has been developed as a program for determining the identify regarding a nucleotide sequence (Altschul et al. (1990) J. Mol. Biol. 215: 403-10). These programs can  
5 be used for the sequence of the present invention. As a specific analysis method, for example, <http://www.ncbi.nlm.nih.gov>. etc. can be referred to.

In addition, a gene having a structure and a function similar to those of rabconnectin-3 $\beta$ , such as an isoform and  
10 an allelic mutant of rabconnectin-3 $\beta$  can be obtained from a cDNA library and a genome library of an animal such as a human being, a mouse, a rat, a rabbit, a hamster, a fowl, a pig, a bovine, a goat, or a sheep by designing primers based on the nucleic acid sequence of SEQ ID NO: 1, in  
15 accordance with a gene amplification technique (PCR) (Current Protocols in Molecular Biology, John Wiley & Sons (1987) Section 6.1-6.4).

The nucleotide sequence of the polynucleotide of the present invention can be confirmed by determining a  
20 sequence with a common method. For example, the confirmation of the nucleotide sequence can be performed by a dideoxynucleotide chain termination method (Sanger et al. (1977) Proc. Natl. Acad. Sci. USA 74: 5463) or the like. Furthermore, the sequence can be analyzed by using an  
25 appropriate DNA sequencer.

<Vector>

According to the present invention, a vector containing the polynucleotide of the present invention is



provided. The vector of the present invention is useful for holding the polynucleotide of the present invention in a host cell and expressing a polypeptide encoded by the polynucleotide. The vector of the present invention includes various vectors such as a plasmid, a cosmid, a virus, a bacteriophage, a cloning vector, and an expression vector (Molecular Cloning, A Laboratory Manual 2nd ed., Cold Spring Harbor Press (1989); Current Protocols in Molecular Biology, John Wiley & Sons (1987)). In a preferable embodiment, the polynucleotide of the present invention is operatively linked to a regulatory sequence so that the polynucleotide of the present invention is expressed in a host cell to which a vector is introduced. The term "regulatory sequence" as used herein includes a promoter, a ribosome binding site, and a terminator in the case where the host cell is a prokaryote and denotes a promoter and a terminator in the case where the host cell is an eukaryote. In some cases, the regulatory sequence may include a transactivator, a transcription factor, a poly(A) signal stabilizing a transcript, a splicing signal, a polyadenylation signal, and the like. Such a regulatory sequence contains all the constituents required for expressing a polynucleotide bound to the regulatory sequence. Furthermore, the vector of the present invention preferably includes a selectable marker. Further, a signal peptide, which is required for translocating a polypeptide expressed in the cells into an endoplasmic reticulum, a periplasm in the case where a Gram-negative bacteria is a host, or outside of the cell, may also be integrated to an

expression vector so that it is added to an intended polypeptide. Furthermore, a linker may be added, and an initiation codon (ATG) and a termination codon (TAA, TAG or TGA) may be integrated, if required.

5           The vector of the present invention is preferably an expression vector. The term "expression vector" denotes a construct capable of expressing a polypeptide encoded in an expression vector *in vitro* or in an intended host cell. The expression vector of the present invention includes a  
10   cloning vector, a binary vector, an integrating vector, and the like. The expression process includes the transcription of a coding sequence in an expression vector to a translatable mRNA, translation from the mRNA to the polypeptide of the present invention, and in some cases,  
15   the secretion of the expressed polypeptide into an endoplasmic reticulum, a periplasm, or outside of the cell.

          An example of a vector enabling the *in vitro* expression of a polypeptide includes pBEST (Promega). Furthermore, examples of a promoter enabling the expression  
20   in a prokaryotic cell host such as *E. coli* include  $P_L$ , *araB* (Better et al. (1988) Science 240: 1041-3), *lacZ* (Ward et al. (1989) Nature 341: 544-6; Ward et al. (1992) FASEB J. 6: 2422-7), *trp*, *tac*, *trc* (fusion of *lac* and *trp*), and the like. Furthermore, terminators derived from *trpA*, a phage,  
25   and *rrnB* ribosomal RNA can be used. Furthermore, an *E. coli* vector preferably includes "ori" for amplifying a vector in a host, and a marker gene for selecting a transformed host. It is preferable to use a drug-resistant gene capable of identifying a host with a drug such as

ampicillin, tetracycline, kanamycin, or chloramphenicol.

In particular, in the case of secreting a polypeptide to a periplasm, a *pelB* signal sequence (Lei et al. (1987) J.

Bacteriol. 169: 4379) can be used. Examples of the vector

5 include M13 vector, pUC vector, pBR322, pCR-Script, pGEX-

5X-1 (Pharmacia), pEGFP, pBluescript (Stratagene), pET

(Invitrogen: as the host in this case, BL21 expressing T7

polymerase is preferable), etc. In particular, examples of

the vector for sub-cloning or cutting include pGEM-T,

10 pDIRECT, pT7, etc.

An example of a host of bacteria other than *E. coli*

includes *Bacillus*, such as pUB110 and pc194 vectors. More

specifically, there are pPL608, pKTH50, and the like

derived from *Bacillus subtilis*. In addition, vectors using,

15 as a host, bacteria of *Pseudomonas* such as *Pseudomonas*

*putida* and *Pseudomonas cepacia*; *Brevibacterium* such as

*Brevibacterium lactofermentum* (pAJ43 (Gene 39: 281 (1985)),

etc.); *Corynebacterium* such as *Corynebacterium glutamicum*

(pCS11 (JP 57-183799 A; pCB101 (Mol. Gen. Genet. 196: 175

20 (1984)) etc.); *Streptococcus* (pHV1301 (FEMS Microbiol. Lett.

26: 239 (1985)); pGK1 (Appl. Environ. Microbiol. 50: 94

(1985)), etc.); *Lactobacillus* (pAM $\beta$ 1 (J. Bacteriol. 137: 614

(1979)), etc.); *Rhodococcus* such as *Rhodococcus rhodochrous*

(J. Gen. Microbiol. 138: 1003 (1992)); and *Streptomyces*

25 such as *Streptomyces lividans* and *Streptomyces virginiae*

(see Genetic Manipulation of *Streptomyces*: A Laboratory

Manual, Hopwood et al., Cold Spring Harbor Laboratories

(1985); pIJ486 (Mol. Gen. Genet. 203: 468-78 (1986)),

pKC1064 (Gene 103: 97-9 (1991)), pUWL-KS (Gene 165: 149-50

(1995))) have been developed. Regarding a vector that can use a microorganism as a host, the documents such as "Microbiology Basic Course 8 Genetic Engineering" (KYORITSU SHUPPAN CO., LTD.) can be referred to. As procedures for  
5 transducing a vector to a bacterium host, a calcium chloride method (Mandel and Higa (1970) J. Mol. Biol. 53: 158-62; Hanahan (1983) J. Mol. Biol. 166: 557-80), electroporation method, and the like can be adopted.

Furthermore, examples of regulatory elements enabling  
10 the expression in a eucaryotic cell host include AOX1 and GAL1 promoters, in the case where yeast is used as a host. Examples of an expression vector derived from yeast include Pichia Expression Kit (Invitrogen), pNV11, SP-Q01, and the like. Vectors that can be used in yeast are described in  
15 Adv. Biochem. Eng. 43: 75-102 (1990), Yeast 8: 423-88 (1992), etc. More specifically, in *Saccharomyces* such as *Saccharomyces cerevisiae*, YRp, YE<sub>p</sub>, YC<sub>p</sub>, and YIp vectors can be used. In particular, an integration vector enabling a multicopy gene transduction and capable of holding a gene  
20 stably (EP537456, etc.) is useful. In addition, in *Kluyveromyces* such as *Kluyveromyces lactis*, 2  $\mu$ m vector derived from *S. cerevisiae*, pKD1 vector (J. Bacteriol. 145: 382-90 (1981)), a vector derived from pGK11, *Kluyveromyces* autonomous replication gene KARS vector, and the like can  
25 be used. In *Schizosaccharomyces*, a vector described in Mol. Cell. Biol. 6: 80 (1986), and pAUR224 (Takara Shuzo Co., Ltd.) can be used. In *Zygosaccharomyces*, a vector derived from pSB3 (Nucleic Acids Res. 13: 4267 (1985)) can be used. In *Pichia* such as *Pichia angusta* or *Pichia pastoris*, a

vector described in the document such as Yeast 7: 431-43  
(1991), Mol. Cell. Biol. 5: 3376 (1985) or Nucleic Acids  
Res. 15: 3859 (1987) can be used. In *Candida* such as  
*Candida maltosa*, *C. albicans*, *C. tropicalis* or *C. utilis*, a  
5 vector described in JP 8-173170 A and a vector using ARS  
derived from *C. maltosa* (Agri. Biol. Chem. 51: 1587 (1987))  
can be used. In *Aspergillus* such as *Aspergillus niger* and  
*A. oryzae*, a vector described in Trends in Biotechnology 7:  
283-7 (1989) can be used. In *Trichoderma*, a vector using a  
10 promoter derived from extracellular cellulase gene  
(Bio/Technology 7: 596-603 (1989)) can be used.

In the case of using mammal and other animal cells as  
a host, adenovirus late promoter (Kaufman et al. (1989) Mol.  
Cell. Biol. 9: 946), CAG promoter (Niwa et al. (1991) Gene  
15 108: 193-200), CMV immediate-early promoter (Seed and  
Aruffo (1987) Proc. Natl. Acad. Sci. USA 84: 3365-9), EF1 $\alpha$   
promoter (Mizushima et al. (1990) Nucleic Acids Res. 18:  
5322; Kim et al. (1990) Gene 91: 217-23), HSV TK promoter,  
SR $\alpha$  promoter (Takebe et al. (1988) Mol. Cell. Biol. 8: 466),  
20 SV40 promoter (Mulligan et al. (1979) Nature 277: 108),  
SV40 early promoter (Genetic Engineering Vol. 3, Williamson  
ed., Academic Press (1982) pp. 83-141), SV40 late promoter  
(Gheysen and Fiers (1982) J. Mol. Appl. Genet. 1: 385-94),  
RSV (Rous sarcoma virus)-LTR promoter (Cullen (1987)  
25 Methods Enzymol. 152: 684-704), MMLV-LTR promoter, CMV  
enhancer, SV40 enhancer, globin intron, and the like can be  
used. Furthermore, it is preferable that a drug-resistant  
gene enabling the identification with a drug such as  
neomycin or G418 is included in a vector. In the case of

increasing the copy number of genes in cells, for example, a vector such as pCHOI is adopted, which uses CHO lacking a nucleic acid synthesis pathway as a host and has a DHFR gene compensating for the lack, and the copy number can be increased by methotrexate (MTX). On the other hand, in order to temporarily express a gene, a vector can be used, which uses a COS cell having a T-antigen gene of SV40 on a chromosome as a host, and has a replication origin of SV40 such as pcD or a replication origin of adenovirus, bovine papilloma virus (BPV), polyoma virus, or the like. Furthermore, as a selection marker for increasing the gene copy number, genes encoding aminoglycoside transferase (APH), thymidinekinase (TK), xanthine guanine phosphoribosyl transferase (Ecogpt), dihydro folic acid reductase (dhfr) and the like may be included. As appropriate vectors, for example, an expression vector pcDV1 of Okayama-Berg (Pharmacia), pCDM8 (Nature 329: 840-2 (1987)), pRc/CMV, pcDNA1, pcDNA3 (Invitrogen), pSPORT1 (GIBCO BRL), pSV2dhfr (Mol. Cell. Biol. 1: 854-64 (1981)), pEF-BOS (Nucleic Acids Res. 18: 5322 (1990)), pCEP4 (Invitrogen), pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, pOP13, pME18S (Mol. Cell. Biol. 8: 466-72 (1988)), etc. are known.

In particular, in order to express the polynucleotide of the present invention in an organism of an animal, adenovirus vector such as pAdexlcw and retrovirus vector such as pZIPneo can be used. A vector can be transduced to a host by an adenovirus method, an electroporation method (Cytotechnology 3: 133 (1990)), a cationic liposome method (Cationic Liposome DOTAP (Boehringer Mannheim), etc.), an

transduction method with a positively charged polymer, an electrostatic type liposome method, an internal type liposome method, a method using a particle gun, a liposome method, lipofection, (Proc. Natl. Acad. Sci. USA 84: 7413 (1987)), a calcium phosphate method (JP 2-227075 A), a receptor-mediated gene transduction method, a retrovirus method, a DEAE dextran method, a virus-liposome method (Separate Volume, Experimental Medicine "Basic Technology of Gene Therapy", Yodosha Co., Ltd. (1997); Separate Volume, Experimental Medicine "Gene Transduction & Expression Analysis Experimental Method, Yodosha Co., Ltd. (1997); J. Clin. Invest. 93: 1458-64 (1994); Am. J. Physiol. 271: R1212-20 (1996); Molecular Medicine 30: 1440-8 (1993); Experimental Medicine 12: 1822-6 (1994); Protein Nucleic Acid Enzyme 42: 1806-13 (1997); Circulation 92 (Suppl. II): 479-82 (1995)), a naked-DNA direct transduction method, and the like. Virus vectors derived from virus other than adenovirus and retrovirus, for example, vectors produced based on Adeno-associated virus, Sindbis virus, Sendai virus, Togavirus, Paramyxovirus, Poxvirus, Poliovirus, Herpesvirus, Lentivirus, vaccinia virus, and the like can be used. Administration into an organism may be performed *ex vivo* or *in vivo*.

In addition, an insect expression system is also known as a system for expressing a heteropolypeptide. For example, an *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector, and a foreign gene can be expressed in *Spodoptera frugiperda* cells or *Trichoplusia* larvae cells. At this time, a target foreign gene is

cloned in a non-essential region of virus. For example, the foreign gene may be operatively linked to a polyhedrin promoter. In this case, a polyhedrin gene is inactivated, and a recombinant virus lacking in a coat protein is  
5 produced. A target polypeptide is expressed in cells of *Spodoptera frugiperda*, *Trichoplusia larvae*, or the like infected with the virus (Smith (1983) J. Virol. 46: 584; Engelhard (1994) Proc. Natl. Acad. Sci. USA 91: 3227-7). In addition, as an expression vector derived from insect  
10 cells, Bac-to-BAC baculovirus expression system (Bigco BRL), pBacPAK8, and the like are known.

In the case of using plant cells as a host, for example, a vector utilizing a 35S promoter of cauliflower mosaic virus or the like can be used. As a method of  
15 transducing a vector to plant cells, a PEG method, an electroporation method, an *Agrobacterium* method, a particle gun method, and the like are known.

A DNA can be inserted to a vector by a ligase reaction using a restriction enzyme site (Current Protocols  
20 in Molecular Biology, John Wiley & Sons (1987) Section 11.4-11.11; Molecular Cloning, A Laboratory Manual 2nd ed., Cold Spring Harbor Press (1989) Section 5.61-5.63).

#### <Transformant>

25 The transformant of the present invention is obtained by transforming a host with the polynucleotide of the present invention, and expresses the protein of the present invention.



## &lt;Host&gt;

According to the present invention, a host containing the polynucleotide or vector of the present invention is provided. For production of the polypeptide of the present invention, *in vitro* and *in vivo* production systems are considered. The host of the present invention includes prokaryotic cells and eucaryotic cells derived from archaeobacteria, bacteria, fungi, plants, insects, fishes, amphibians, reptiles, birds, and mammals. The host of the present invention includes a polynucleotide encoding the polypeptide of the present invention in cells. The polynucleotide should not be placed at a naturally occurring position on a genome of a host cell, and may be under the control of a promoter of the polynucleotide itself, transduced in a genome, and held as an extrachromosomal structure.

Examples of the bacterium host include Gram-positive and Gram-negative bacteria belonging to *Escherichia*, *Streptococcus*, *Staphylococcus*, *Serratia*, *Bacillus*, and the like, such as *E. coli* (JM109, DH5 $\alpha$ , HB101, XL1Blue), *Serratia marcescens* and *Bacillus subtilis*.

The eucaryotic host includes cells such as fungi such as yeast, higher plants (cells derived from *Nicotiana tabacum*), insects (*Drosophila* S2, *Sporodoptera* Sf9, Sf21, Tn5), fishes, amphibians (*Xenopus laevis* oocyte (Valle et al. (1981) *Nature* 291: 358-40)), reptiles, birds, and mammals (CHO (J. Exp. Med. 108: 945 (1995); among them, a DHFR-gene deficient dhfr-CHO (Proc. Natl. Acad. Sci. USA 77: 4216-20 (1980) and CHO K-1 (Proc. Natl. Acad. Sci. USA

60: 1275 (1968)) are preferable), COS, Hela, C127, 3T3, BHK, HEK293, Bowes melanoma cells), myeloma, Vero, Namalwa, Namalwa KJM-1, HBT5637 (JP 63-299 A), and plants (potato, tobacco, corn, rice, oil-seed rape, soybean, tomato, wheat, 5 barley, rye, alfalfa, flax, etc.). As the fungi, in addition to the yeast such as *Saccharomyces cerevisiae* belonging to *Saccharomyces* or one belonging to *Pichia*, an expression system using cells of *Aspergillus niger* belonging to *Aspergillus* of a filamentous fungi or the like 10 is also known.

A vector is transduced to a host cell by an electroporation method (Chu et al. (1987) Nucleic Acids Res. 15: 1311-26), a cationic liposome method, an electric pulse perforation method (Current Protocols in Molecular Biology, 15 John Wiley & Sons (1987) Section 9.1-9.9), a direct injection method using a minute glass tube, microinjection method, lipofection (Derijard (1994) Cell 7: 1025-37; Lamb (1993) Nature Genetics 5: 22-30; Rabindran et al. (1993) Science 259: 230-4), a lipofectamine method (GIBCO-BRL), a 20 calcium phosphate method (Chen and Okayama (1987) Mol. Cell. Biol. 7: 2745-52), a DEAE dextran method (Lopata et al. (1984) Nucleic Acids Res. 12: 5707-17; Sussman and Milman (1985) Mol. Cell. Biol. 4: 1642-3), FuGene 6 reagent (Boehringer-Mannheim), or the like.

25 The production method of the present invention is a method of producing the protein of the present invention, i.e., a rabconnectin-3-binding protein, and includes culturing the transformant of the present invention and collecting a rabconnectin-3-binding protein which is

produced by the transformant from a culture. More specifically, the method described in the above-mentioned <Production of a protein> can be used.

Rabconnectin-3 $\beta$  and rabconnectin-3 $\alpha$  are co-  
5 immunoprecipitated even with either one of an anti-rabconnectin-3 $\alpha$  antibody and an anti-rabconnectin-3 $\beta$  antibody. Both the proteins are not separated from each other in the presence of 0.5 M NaCl or 1% CHAPS. However, they are partially separated from each other in the  
10 presence of 1 M NaCl, and completely separated from each other in the presence of 1% deoxycholate. Furthermore, these two proteins coexist in synaptic vesicles. These results show that rabconnectin-3 $\alpha$  and -3 $\beta$  constitute a sub-unit structure.

15 It is shown that rabconnectin-3 $\alpha$  does not have a transmembrane portion, but binds to synaptic vesicles (see The Journal of Biological Chemistry, 2002, Vol. 277, No. 12, PP. 9629-9632). Rabconnectin-3 $\alpha$  is separated from vesicles in the presence of a surfactant such as Triton X-100 and  
20 NP-40, which suggests that this protein is one of peripheral membrane proteins of synaptic vesicles. Similarly, rabconnectin-3 $\beta$  does not have a transmembrane portion, and is separated from vesicles in the same situation as the above, which suggests that this protein is  
25 also one of peripheral membrane proteins of synaptic vesicles.

Rabconnectin-3 $\beta$  directly binds to Rab3 GEP stoichiometrically, whereas rabconnectin-3 $\alpha$  does not bind. A complex of rabconnectin-3 $\alpha$  and -3 $\beta$  directly binds to Rab3

GEP; however, this binding is much smaller than that of rabconnectin-3 $\beta$  in terms of stoichiometry. Therefore, this suggests that the interaction between 3 $\alpha$  and 3 $\beta$  covers its binding site so that Rab3 GEP does not bind to the complex.

5 In contrast, none of rabconnectin-3 $\alpha$ , -3 $\beta$ , and a complex thereof binds to Rab3 GAP. This suggests that rabconnectin-3 $\beta$  indirectly binds to Rab3 GAP, probably via unidentified molecules.

The rabconnectin-3 and GDP/GTP exchange protein can  
10 be obtained as described in J. Biol. Chem., 272, 3875-3878 (1997), J. Biol. Chem., 273, 24781-24785, JP 10-210971 A, and the like.

#### <Probe>

15 According to the present invention, a probe with respect to the polynucleotide of the present invention is provided. The probe of the present invention is composed of a polynucleotide having at least 15 nucleotides complementary to the polynucleotide of the present  
20 invention. The term "complementary sequence" as used herein means not only ones in the form of at least 15 continued bases in a nucleotide sequence being completely paired with respect to a template, but also ones in the form of at least 70%, preferably 80%, more preferably 90%,  
25 and most preferably 95% or more (e.g., 97% or 99%) of the bases in the nucleotide sequence being paired. The term "paired bases" means that a chain is formed so that T (U in the case of RNA) corresponds to A, A corresponds to T or U, G corresponds to C, and C corresponds to G in a nucleotide

sequence of a polynucleotide to be a template. The  
homology can be determined by the same method as that in  
the case of the above-mentioned polynucleotide to be  
hybridized. The probe of the present invention is  
5 preferably composed of a part of the polynucleotide of the  
present invention, i.e., a polynucleotide having at least  
15 continued nucleotides. By using the probe of the  
present invention, the polynucleotide of the present  
invention can be detected or isolated. Furthermore, the  
10 expression of a gene encoding the protein of the present  
invention can be analyzed. Furthermore, the localization  
of the expression can be analyzed. Samples to be measured  
are organs, tissues, cells, and the like.

The analysis of the polynucleotide of the present  
15 invention or the analysis of the gene encoding the protein  
of the present invention, using a probe, can be performed  
by hybridizing the probe with a subject polynucleotide.  
Usually, it is performed by hybridizing a probe with a  
subject polynucleotide, detecting the hybrid thus obtained,  
20 and analyzing the detection result. The analysis of the  
detection result includes the measurement (including  
detection, quantitative determination) of the  
polynucleotide or the gene, and the detection of the  
localization of the polynucleotide or the gene. The  
25 subject polynucleotide may be present in a subject tissue  
or a subject cell.

#### <Primer>

According to the present invention, a primer with

respect to the polynucleotide of the present invention is provided. Such a primer of the present invention is composed of a polynucleotide having at least 15 nucleotides complementary to the polynucleotide of the present invention, and can be used for detecting or amplifying the polynucleotide of the present invention. Usually, in the case where the polynucleotide is used as a primer, it is desirably composed of 15 to 100 bases, and preferably 15 to 35 bases. In the case where the polynucleotide is used as a primer, it is desirably composed of at least 15 bases, and preferably 30 bases. In the case of the primer, the nucleotide can be designed so as to have a structure in which the region on a 3'-terminus side is set to be a sequence complementary to a target sequence, and a restriction enzyme recognition sequence, tag, or the like is added to a 5'-terminus side. The primer of the present invention can be hybridized with the polynucleotide of the present invention. The primer of the present invention is preferably composed of a part of the polynucleotide of the present invention, i.e., a polynucleotide having at least 15 continued nucleotides. By using the primer of the present invention, the polynucleotide of the present invention can be detected or isolated. Furthermore, the expression of a gene encoding the protein of the present invention can be analyzed. Furthermore, the localization of the expression can be analyzed. Samples to be measured are organs, tissues, cells, and the like. Needless to say, mRNA can be amplified by RT-PCR, using these primers. Furthermore, mRNA in a sample can also be quantified by

quantitative RT-PCR.

The analysis of the polynucleotide of the present invention or the analysis of the gene encoding the protein of the present invention, using a primer, can be performed  
5 by hybridizing the primer with a subject polynucleotide. Usually, it is performed by hybridizing a primer with a subject polynucleotide to amplify the polynucleotide (i.e., PCR is performed using a primer, with the subject polynucleotide (reverse transcription is performed, if  
10 required) being a template, detecting an amplified product, and analyzing the detection results. The analysis of the detection result includes the measurement (including detection and quantitative determination) of the polynucleotide or the gene, and the detection of the  
15 localization of the polynucleotide or the gene. The subject polynucleotide may be present in a subject tissue or a subject cell.

#### <Antisense>

20 According to the present invention, an antisense polynucleotide with respect to the polynucleotide of the present invention is provided. The antisense polynucleotide of the present invention suppresses the expression of the polynucleotide of the present invention  
25 in cells by binding mRNA or DNA.

The mechanisms of suppressing the expression of a target gene by an antisense polynucleotide may be as follows: (1) inhibition of transcription initiation by forming a triple helix, (2) suppression of transcription by

forming a hybrid with a local open-loop structure site formed by RNA polymerase, (3) inhibition of transcription by forming a hybrid with RNA in the course of synthesis, (4) suppression of splicing by forming a hybrid at a junction point of intron-exon, (5) suppression of splicing by forming a hybrid with a spliceosome forming site, (6) suppression of transition of mRNA to a cytoplasm by forming a hybrid with mRNA, (7) suppression of splicing by forming a hybrid with a capping site or a poly-A addition site, (8) suppression of translation initiation by forming a hybrid with a translation initiation factor binding site, (9) suppression of translation by forming a hybrid with a ribosome binding site, (10) suppression of elongation of a peptide chain by forming a hybrid with an mRNA translation region or a polysome binding site, and (11) suppression of gene expression by forming a hybrid with an interaction site of a nucleic acid and a protein (Hirashima and Inoue, "New Biochemistry Experimental Course 2, Nucleic Acid IV, Replication and Expression of Gene", edited by Nihon Seikagaku-kai, Tokyo Kagaku Dojin, pp. 319-347 (1993)).

The antisense polynucleotide included in the present invention may suppress the expression of a gene by any of the above mechanisms (1) to (11). More specifically, the antisense polynucleotide may include an antisense sequence with respect to a sequence in a non-translation region, as well as a translation region of a gene intended to be inhibited for expression. DNA encoding an antisense polynucleotide can be used by operatively linking it to an appropriate regulatory sequence enabling the expression.



It is not necessarily required that the antisense polynucleotide is completely complementary to a translation region or a non-translation region of a target gene, and only needs to inhibit the expression of the gene effectively. Such an antisense polynucleotide has a chain length of at least 15 bp, preferably 100 bp or more, more preferably 500 bp or more, generally 3000 bp or less, preferably 2000 bp or less, and more preferably 1000 bp or less, and has a homology of preferably 90% or more, and more preferably 95% or more with respect to a complementary chain of a transcript product of the target gene. Such an antisense polynucleotide can be prepared by a phosphorothionate method (Stein (1988) Nucleic Acids Res. 16: 3209-21), etc. based on the polynucleotide of the present invention.

#### <Ribozyme>

According to the present invention, a ribozyme with respect to the polynucleotide of the present invention is provided. The ribozyme of the present invention suppresses the expression of the polynucleotide of the present invention in cells by binding mRNA or DNA.

The ribozyme is a generic name for catalysts containing RNA as a constituent component, and is roughly classified into large ribozyme and small ribozyme. The large ribozyme is an enzyme which cuts a phosphate bond of a nucleic acid, and leaves 5'-phosphoric acid and 3'-hydroxyl group at a reaction site after reaction. The large ribozyme is further classified into (1) group I intron RNA

that performs transesterification at a 5'-splice site with guanosine, (2) group II intron RNA that performs self-splicing in two-stage reactions through a lariat structure, and (3) a RNA component of ribonuclease P that cuts a tRNA precursor on a 5'-side by hydrolysis. In contrast, the small ribozyme is a relative small structural unit (about 40 bp), and cuts an RNA to generate a 5'-hydroxyl group and 2'-3' cyclic phosphoric acid. The small ribozyme includes ribozymes of a hammer head type (Koizumi et al. (1988) FEBS Lett. 228: 225), a hairpin type (Buzayan (1986) Nature 323: 349; Kikuchi and Sasaki (1992) Nucleic Acids Res. 19: 6751; Hiroshi Kikuchi (1992) Chemistry and Biology 30: 112), and the like. Regarding the ribozyme, various modified methods are known, since the ribozyme is altered and synthesized easily. For example, by designing the ribozyme so that a substrate binding portion thereof is complementary to a RNA sequence close to a target site, a hammer head type ribozyme can be produced, which recognizes and cuts a basic sequence UC, UU, or UA in a target RNA (Koizumi et al. (1988) FEBS Lett. 228: 225; Makoto Koizumi and Eiko Ohtsuka (1990) Protein nucleic acid enzyme 35: 2191; Koizumi et al. (1989) Nucleic Acids Res. 17: 7059). The hair pin type ribozyme can also be designed and produced in accordance with a known method (Kikuchi and Sasaki (1992) Nucleic Acids Res. 19: 6751; Hiroshi Kikuchi (1992) Chemistry and Biology 30: 112).

The antisense polynucleotide and ribozyme of the present invention can also be used for gene therapy with *ex vivo* method or *in vivo* method, as a vector derived from

virus such as retrovirus, adenovirus, and adeno-associated virus, a non-virus vector using liposome or the like, or naked DNA, in order to regulate the expression of a gene in cells.

5           The nucleotide sequence of the antisense polynucleotide and ribozyme of the present invention can be confirmed by the same method as that of the polynucleotide described above.

10   <RNA interference>

          According to the present invention, a double-stranded RNA that makes a cut by RNA interference with respect to the polynucleotide of the present invention is provided. The double-stranded RNA of the present invention suppresses  
15   the expression of the polynucleotide of the present invention in cells by binding an mRNA and being cut enzymatically (Fire et al. (1998) Nature 391: 806-811; Takashi Morita et al., (2002) Protein, Nucleic acid, Enzyme 47: 1939-1945).

20           The double-stranded RNA of the present invention can also be used for gene therapy with ex vivo method or in vivo method, as a vector derived from virus such as retrovirus, adenovirus, adeno-associated virus, a non-virus vector using liposome or the like, or naked DNA, in order  
25   to regulate the expression of a gene in cells.

          The antisense polynucleotide and ribozyme of the present invention, and the double-stranded RNA that makes a cut by RNA interference with respect to the polynucleotide of the present invention can reduce an mRNA encoding the

protein of the present invention. Thus, they can reduce the protein of the present invention. Furthermore, the antisense polynucleotide and ribozyme of the present invention, and the double-stranded RNA that makes a cut by RNA interference with respect to the polynucleotide of the present invention function as an inhibition reagent of the rabconnectin-3-binding protein, so that they are useful as a reagent for analyzing the function of the protein of the present invention.

10           In the present invention, it is confirmed that the rabconnectin-3-binding protein localizes in a synapse, and binds rabconnectin-3 and a GDP/GTP exchange protein. Based on this, it is considered that the rabconnectin-3-binding protein participates in the regulation of the transportation of synaptic vesicles. Therefore, the material inhibiting the rabconnectin-3-binding protein may participate in diseases considered to be caused by the abnormality of the transportation of synaptic vesicles (e.g., intellectual disorder (mental retardation), attention deficit hyperactivity disorder, autistic disorder, learning disorder, etc.). Thus, the antisense polynucleotide and ribozyme of the present invention, and the double-stranded RNA that makes a cut by RNA interference with respect to the polynucleotide of the present invention can be used as an effective ingredient of therapeutic agents for these diseases having an inhibition action to the protein of the present invention.

<Antibody>

According to the present invention, an antibody to the polypeptide of the present invention or its polypeptide fragment is provided. The antibody of the present invention includes a polyclonal antibody, a monoclonal antibody, a chimera antibody, a single-stranded antibody (scFV) (Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-83; The Pharmacology of Monoclonal Antibody, Vol. 113, Rosenberg and Moore ed., Springer Verlag (1994) pp. 269-315), a humanized antibody, a multispecific antibody (LeDoussal et al. (1992) Int. J. Cancer Suppl. 7: 58-62; Paulus (1985) Behring Inst. Mitt. 78: 118-32; Millstain and Cuello (1983) Nature 305: 537-9; Zimmermann (1986) Rev. Physiol. Biochem. Pharmacol. 105: 176-260; Van Dijk et al. (1989) Int. J. Cancer 43: 944-9), and antibody fragments such as Fab, Fab', F(ab')<sub>2</sub>, Fc, and Fv. Furthermore, the antibody of the present invention may be modified with PEG or the like, if required. In addition, the antibody of the present invention may be produced as a fusion protein with  $\beta$ -galactosidase, a maltose binding protein, GST, a green fluorescent protein (GFP), etc., and may be designed so as to be detected without using a secondary antibody. Furthermore, the antibody of the present invention may be altered by labeling an antibody with biotin, etc. so as to enable collection of an antibody using avidin, streptoavidin, etc.

The antibody of the present invention can be produced using the polypeptide of the present invention or a fragment thereof, or cells expressing them as a sensitized antigen. Furthermore, the polypeptide of the present

invention or a short fragment thereof may bind a carrier such as bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, etc. to be used as an immunogen. Furthermore, known adjuvants such as an aluminum adjuvant, complete (or  
5 incomplete) Freund's adjuvant, pertussis adjuvant, and the like can be used for enhancing an immune response to an antigen, together with the polypeptide of the present invention or its fragment.

A polyclonal antibody is obtained, for example, as  
10 follows: a mammal is immunized with the polypeptide of the present invention or a fragment thereof, together with a desired adjuvant, and serum is obtained from the immunized animal. There is no particular limit to mammals used here and animals of rodentia, lagomorpha, and primates are  
15 generally used. Examples of the mammals include rodentia such as a mouse, a rat, a hamster, etc.; lagomorpha such as a rabbit; and primates such as monkeys (e.g., crab-eating monkey, rhesus monkey, hamadryad, chimpanzee, etc.). An animal is immunized by injecting the animal with the  
20 solution thus obtained intraperitoneally or subcutaneously after appropriately diluting and suspending a sensitization antigen in phosphate-buffered saline (PBS), a saline, etc., and optionally mixing an adjuvant with the resultant solution, to emulsify the solution. Thereafter, preferably,  
25 the sensitization antigen mixed with Freund's complete adjuvant is administered to the animal several times every 4 to 21 days. The production of an antibody can be confirmed by measuring a desired antibody level in the serum by a conventional method. Finally, the serum itself

may be used as a polyclonal antibody, or may be further purified. Regarding a specific method, for example, "Current Protocols in Molecular Biology" (John Wiley & Sons (1987) Section 11.12-11.13) can be referred to.

5           In order to produce a monoclonal antibody, first, the spleen is isolated from an animal immunized in the above-mentioned manner, an immunocytes are separated from the spleen, and the immunocytes are fused with appropriate myeloma cells, using polyethylene glycol (PEG) or the like  
10   to prepare hybridomas. The fusion of the cells can be performed in accordance with a method of Milstein (Galfre and Milstein (1981) Methods Enzymol.73: 3-46). Herein, in particular, examples of appropriate myeloma cells include those which enable fused cells to be selected with a drug.  
15   In the case of using such myelomas, the fused hybridomas are selected by culture in a culture medium (HAT medium) containing hypoxanthine, aminopterin, and thymidine in which cells other than the fused cells will die. Then, a clone producing an antibody that binds the polypeptide of  
20   the present invention or a fragment thereof is selected from the hybridoma thus prepared. Thereafter, the selected clone is implanted to the abdominal cavity of a mouse or the like, and ascites is collected to obtain a monoclonal antibody. Furthermore, regarding a specific method,  
25   "Current Protocols in Molecular Biology" (John Wiley & Sons (1987) Section 11.4-11.11) can be referred to.

A hybridoma can also be obtained by a method of sensitizing human lymphocytes infected with EB virus *in vitro*, using an immunogen, fusing the sensitized

lymphocytes with myeloma cells derived from a human being (U266, etc.), thereby obtaining a hybridoma that produces a human antibody (JP 63-17688 A). Furthermore, a human antibody can also be obtained by using antibody-producing  
5 cells prepared by sensitizing a transgenic animal having a repertoire of a human antibody gene (W092/03918; W093/02227; W094/02602; W094/25585; W096/33735; W096/34096; Mendez et al. (1997) Nat. Genet. 15: 146-56, etc.). An example that does not use a hybridoma includes a method of  
10 transducing a cancer gene to an immunocyte such as lymphocyte and the like producing an antibody, thereby making the immunocyte immortal.

Furthermore, an antibody can be produced by genetic engineering (see Borrebaeck and Larrick (1990) Therapeutic  
15 Monoclonal Antibodies, MacMillan Publishers LTD., UK). In order to produce an antibody, first, a gene encoding an antibody is cloned from a hybridoma or antibody-producing cells (sensitized lymphocytes, etc.). The gene thus obtained is integrated in an appropriate vector, the vector  
20 is transduced to a host, and the host is cultured, whereby an antibody is produced. Such a recombinant antibody is also included in the antibody of the present invention. Representative examples of the recombinant antibody include a chimera antibody composed of a variable region derived  
25 from a non-human antibody and a constant region derived from a human antibody, and humanized antibody composed of a complementary determining region derived from a non-human antibody (CDR), a framework region (FR) derived from a human antibody, and a constant region (Jones et al. (1986)



Nature 321: 522-5; Reichmann et al. (1988) Nature 332: 323-9; Presta (1992) Curr. Op. Struct. Biol. 2: 593-6; Methods Enzymol. 203: 99-121 (1991)).

The antibody fragment of the present invention can be produced by treating the above-mentioned polyclonal or monoclonal antibody with an enzyme such as papain or pepsin. Alternatively, the antibody fragment of the present invention can also be produced in a genetic engineering manner, using a gene encoding an antibody fragment (see Co et al., (1994) J. Immunol. 152: 2968-76; Better and Horwitz (1989) Methods Enzymol. 178: 476-96; Pluckthun and Skerra (1989) Methods Enzymol. 178: 497-515; Lamoyi (1986) Methods Enzymol. 121: 652-63; Rousseaux et al. (1986) 121: 663-9; Bird and Walker (1991) Trends Biotechnol. 9: 132-7).

The multispecific antibody of the present invention includes a bispecific antibody (BsAb), a diabody (Db), and the like. The multispecific antibody can be produced by a method of: (1) chemically coupling different specific antibodies to each other with a hetero-bifunctional linker (Paulus (1985) Behring Inst. Mill. 78: 118-32); (2) fusing a hybridoma that secretes different monoclonal antibodies (Millstein and Cuello (1983) Nature 305: 537-9); (3) transfecting an eucaryotic cell expression system such as mouse myeloma cells with light chain and heavy chain genes (four kinds of DNAs) of different monoclonal antibodies, and thereafter isolating a monovalent portion of a bispecific antibody (Zimmermann (1986) Rev. Physio. Biochem. Pharmacol. 105: 176-260; Van Dijk et al. (1989) Int. J. Cancer 43: 944-9); or the like. On the other hand, Db is

an antibody fragment of a dimer composed of two divalent polypeptide chains that can be configured by gene fusion, and can be produced by known procedures (see Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-8; EP404097; WO93/11161).

The collection and purification of an antibody and an antibody fragment can also be performed by using proteins A and G, and by a protein purification technique described in detail in <Production of a protein> (Antibodies: A Laboratory Manual, Ed Harlow and David Lane, Cold Spring Harbor Laboratory (1988)). For example, in the case of using protein A for purifying the antibody of the present invention, a protein A column such as Hyper D, POROS, and Sepharose F.F. (Pharmacia) is known and can be used. The concentration of the thus-obtained antibody can be determined by measuring its absorbance or by enzyme-linked immunosorbent assay (ELISA), etc.

The antigen binding activity of an antibody can be measured by absorbance measurement, a fluorescent antibody method, enzyme immunoassay (EIA), radioimmunoassay (RIA), ELISA, or the like. In the case of measuring the antigen binding activity by ELISA, the antibody of the present invention is immobilized on a carrier such as a plate, the polypeptide of the present invention is added to the plate, and a sample containing an intended antibody is added thereto. Herein, as a sample containing an antibody, a culture supernatant of antibody-producing cells, a purified antibody, and the like are considered. Then, a secondary antibody recognizing the antibody of the present invention

is added to the plate, and the plate is incubated.

Thereafter, the plate is washed, and a label added to the secondary antibody is detected. More specifically, in the case where the secondary antibody is labeled with alkali

5 phosphatase, a substrate of the enzyme such as p-nitrophenyl phosphate is added to the plate to measure the absorbance, whereby the antigen binding activity can be measured. Furthermore, a commercially available system such as BIAcore (Pharmacia) can also be used for the  
10 evaluation of the activity of an antibody.

The antibody of the present invention can be used as a reagent for detecting the rabconnectin-3-binding protein. That is, an immunohistological analysis method can be performed using the antibody of the present invention.

15 Thus, the present invention provides an immunohistological analysis method, e.g., a method of analyzing the expression amount of a protein and a method of analyzing the localization of a protein. Examples of the immunohistological analysis method include enzyme  
20 immunoassay (EIA), radioimmunoassay (RIA), ELISA, Western blotting, flow cytometry, immunohistochemical staining, and the like. Furthermore, the antibody of the present invention can be used for purifying the polypeptide of the present invention and a fragment thereof.

25 According to the present invention, it is confirmed that the rabconnectin-3-binding protein localizes in a synapse. Based on this, the detection using the antibody of the present invention can also be performed, using the rabconnectin-3-binding protein as a marker of a synapse.

Thus, the antibody of the present invention can be used as a reagent for detecting a synapse, if required.

Furthermore, it is confirmed that the protein of the present invention binds rabconnectin-3 and a GDP/GTP

5 exchange protein. Therefore, the antibody of the present invention can be used for detecting them.

<Screening method of the present invention>

The protein of the present invention binds  
10 rabconnectin-3 and a Rab3 GDP/GTP exchange protein. Thus, the protein of the present invention can be used for screening a material that increases or decreases the binding. Although the protein of the present invention is derived from a human being, a heterogeneous homologous  
15 protein having the same activity as that of the protein of the present invention, which is present in other species such as a rat, can also be used for the above purpose in the same way as in the protein of the present invention. Thus, there is provided a method of screening a candidate  
20 material for promoting or inhibiting the binding between the protein of the present invention or the rabconnectin-3-binding protein that is a heterogeneous homologous protein thereof and rabconnectin-3, comprising: reacting the rabconnectin-3-binding protein and rabconnectin-3 with each  
25 other in the presence and absence of the candidate material, and selecting the candidate material that increases or decreases the binding. There is also provided a method of screening a candidate material for promoting or inhibiting the binding between the protein of the present invention or

the Rab3 GDP/GTP exchange protein-binding protein that is a heterogenous homologous protein thereof, and the Rab3 GDP/GTP exchange protein, comprising: reacting the Rab3 GDP/GTP exchange protein-binding protein and the Rab3 GDP/GTP exchange protein with each other in the presence and absence of the candidate material, and selecting the candidate material that increases or decreases the binding.

The measurement of the binding between the rabconnectin-3-binding protein and rabconnectin-3, and the binding between the Rab3 GDP/GTP exchange protein-binding protein and the Rab3 GDP/GTP exchange protein can be performed in accordance with a known method of measuring the binding between the proteins.

It is considered that the protein of the present invention and a heterogeneous homologous protein thereof, that is P160, participate in the regulation of the transportation of synaptic vesicles such as neurotransmitter release and the like. Therefore, it is considered that the material thus selected, which promotes or inhibits the binding, can be used as an active ingredient for a therapeutic agent for diseases (e.g., intellectual disorder (mental retardation), attention deficit hyperactivity disorder, autistic disorder, learning disorder, etc.) caused by the abnormality of the transportation of the synaptic vesicles.

Such therapeutic agents (pharmaceuticals) can be produced by preparing a material (active ingredient) selected by screening. Preparation can be performed appropriately in accordance with a conventional method,

depending upon the kind of the selected material, the type of preparation, etc. The pharmaceuticals may be included a pharmaceutical composition comprising an active constituent and a pharmaceutically acceptable carrier.

5

#### EXAMPLES

The present invention will be described in detail by way of the following examples. It should be noted that the present invention is not limited to the examples.

10

##### Example 1

(1) Preparation of rat proteins coimmunoprecipitated with Rab3 GEP

A CSV fraction extract of rat brain was coimmunoprecipitated with an anti-Rab3 GEP antibody in accordance with a method described in J. Biol. Chem., 277, 9629-9632 (2002), and a precipitate was electrophoresed. More specifically, a CSV fraction was prepared from rat brain as described in the above document. The fraction was extracted with Buffer A (20 mM Tris/HCl (pH 7.5), 1 mM EDTA, 1 mM DTT, 0.8% n-octylglucopyranoside), and the extract was incubated overnight at 4°C with the anti-Rab3 GEP antibody immobilized on protein A Sepharose beads (20  $\mu$ l wet weight). After the beads were extensively washed with Buffer A, bound proteins were eluted by boiling the beads in an SDS sample buffer (60 mM Tris/HCl (pH 6.7), 3% SDS, 2% (v/v) 2-mercaptoethanol, 5% glycerol). The sample was subjected to SDS-PAGE, followed by the protein staining. Consequently, two proteins (Band No.2) coimmunoprecipitated with Rab3 GEP,

as well as rabconnectin-3 (Band No. 1), p160 (Band No. 3), and p60 (Band No. 4), were detected (A in Fig. 1).

Band No. 3 was cut out from the gel and digested with trypsin, and the peptides were subjected to mass spectrometric analysis. Computer database search revealed that p160 includes an amino acid sequence deduced from a human cDNA fragment (KIAA0541, GenBank accession No. AB011113).

As described in the following (5), p160 was found to form a complex with rabconnectin-3. Therefore, hereinafter, p160 and rabconnectin-3 will be referred to as rabconectin-3 $\beta$  and rabconectin-3 $\alpha$ , respectively.

## (2) Molecular cloning and determination of primary structure

KIAA0541 cDNA contained a coding region of about 3.5 kb and an inframe stop codon, but lacked a predicted initiation codon. Furthermore, the sequence of KIAA0541 cDNA was included in BAC clones of the human genome (GenBank Accession Nos. AC007052 and AC008006). On the basis of this information, PCR was performed so as to obtain a 5'-terminus region of human rabconnectin-3 $\beta$  cDNA. More specifically, a set of primers having sequences: ATG GCA GGA AAC AGC CTT GTT CTA CCC ATT GTT C (SEQ ID NO: 3)/GTT GTC ATT GCC AGC CCT TCT TCA CTT CCC (SEQ ID NO: 4) was designed. A cDNA fragment was amplified using these primers from a human heart cDNA (CLONTECH). A PCR product was subcloned to a pCR4 Blunt vector (Invitrogen). DNA sequencing was performed by a dideoxy nucleotide

termination method using a DNA sequencer (ABI PRISM 3100 Genetic Analyzer, PE Biosystems). As a result, a cDNA fragment containing about a 1.0 kb coding region and a predicted initiation codon was obtained.

5       The full length of human rabconnectin-3 $\beta$  cDNA was obtained by ligation of the above cDNA fragment to KIAA0541 cDNA (SEQ ID NO: 1). A encoded protein consisted of 1,490 amino acids, and showed a calculated molecular weight of 163,808 (SEQ ID NO: 2). The human rabconnectin-3 $\beta$

10       contained 7 WD domains (B in Fig. 1). In order to confirm whether the ligated cDNA encodes the full-length human rabconnectin-3 $\beta$ , the cDNA was transfected into HEK293 cells. The cell extract was subjected to SDS-PAGE, followed by Western blotting with an anti-rabconnectin-3 $\beta$  antibody.

15       More specifically, pCMVF $\alpha$  rabconnectin-3 $\beta$  (see the following (3)) was transfected into HEK293 cells, a lysate of the cells was subjected to SDS-PAGE (10% polyacrylamide gel), followed by Western blotting with an anti-rabconnetin-3 $\beta$ -1 antibody (see the following (3)). As a

20       control, the HEK293 cell lysate and homogenate of rat brain were similarly subjected to SDS-PAGE, followed by the Western blotting. As a result, a protein with a molecular weight of about 160 kDa was detected (C in Fig. 1). In C of Fig. 1, each lane was as follows: Lane 1, control HEK293

25       cells (1  $\mu$ g protein); Lane 2, pCMVF $\alpha$  rabconectin-3 $\beta$ -transfected HEK293 cells (1  $\mu$ g protein); and Lane 3, homogenate of rat brain (20  $\mu$ g protein).

      The above-mentioned molecular weight was the same as that of native rabconnective-3 $\beta$  derived from rat brain.



Therefore, it was concluded that the cDNA encodes the full length of the human rabconnectin-3 $\beta$ . The human rabconnectin-3 $\beta$  showed a domain structure similar to rat TRAG (GenBank Accession No. AF305813) and human WDR7 (GenBank Accession No. XM028588). Hitherto, the TRAG was identified as a protein expressed in a TGF- $\beta$ -resistant cell line; however, its function is unknown (Cytogenet. Cell Genet. 88, 324-325, 2000).

10 (3) Preparation of an antibody to rabconnectin-3 $\beta$

An expression vector of rabconnectin-3 $\beta$  was constructed using pGex4T-1 (Amersham Biosciences Inc). The construct contained the following amino acid sequences of rabconnectin-3 $\beta$ : pGex4T-1 rabconnectin 3 $\beta$ -1, amino acid numbers 487-625; pGex4T-1 rabconnectin 3 $\beta$ -2, amino acid numbers 615-920.

A GST fusion protein was expressed in *E. coli*, and purified by use of glutathione Sepharose beads (Amersham Biosciences Inc.). A rabbit polyclonal anti-rabconnectin-3 $\beta$ -1 and -2 antibodies were produced by using GST-rabconnectin-3 $\beta$ -1 and -2, respectively, as antigens, and affinity-purified with each antigen covalently coupled to NHS-activated Sepharose beads (Amersham Biosciences Inc.).

25 (4) Study of tissue distribution and subcellular distribution of rabconnectin-3 $\beta$

The tissue distribution and subcellular distribution of rabconnectin-3 $\beta$  was studied. Regarding the tissue distribution, homogenates of various rat tissues (each 20

$\mu$ g protein) were subjected to SDS-PAGE, followed by Western blotting with an anti-rabconnectin-3 $\beta$ -2 antibody.

Regarding the subcellular distribution, a homogenate of rat cerebra was subjected to subcellular fractionation (J. Biol. Chem., 265, 11872-11879 (1990)), and each fraction (each 10  $\mu$ g protein) was subjected to SDS-PAGE, followed by Western blotting with an anti-rabconnectin-3 $\beta$ -1 antibody, an anti-rabconnectin-3 $\alpha$  antibody, or an anti-Rab3 GEP antibody.

As a result, the tissue distribution analysis revealed that the rabconnectin-3 $\beta$  was specifically expressed in the brain (A in Fig. 2). The subcellular distribution analysis in the brain revealed that rabconnectin-3 $\beta$  is highly concentrated in a CSV fraction (B in Fig. 2). The symbols in B of Fig. 2 represent the following fractions and the like: Rc-3 $\beta$ , rabconnectin-3 $\beta$ ; Rc-3 $\alpha$ , rabconnectin-3 $\alpha$ ; GEP, Rab3 GEP; Ho, homogenate fraction; P1, nuclear pellet fraction; P2, crude synaptosome fraction; P3, microsome fraction; S, soluble cytosol fraction; P2A, myelin fraction; P2B, endoplasmic reticulum and Golgi complex fraction; P2C, synaptosome fraction; P2D, mitochondria fraction; SS, synaptic soluble fraction; CSV, crude synaptic vesicle fraction; and CSM, crude synaptic membrane fraction. The results shown in the figure are representative of three independent experiments.

Furthermore, regarding a mouse hippocampus and a primary culture of rat hippocampus neurons (J. Biol. Chem., 277, 9629-9632 (2002)), an immunoelectron microscope observation was performed (Biochem. Biophys. Res. Commun., 202, 1235-1243 (1994)).

A sample was doubly stained with an anti-rabconnectin-3 $\alpha$  antibody and an anti-rabconnectin-3 $\beta$ -2 antibody, followed by immunofluorescence microscopy.

As a result, it was revealed that rabconnectin-3 $\beta$  is  
5 colocalized with rabconnectin-3 $\alpha$  in a synapse region of the mouse hippocampus and the primary culture of rat hippocampus neurons (Aa and Ab in Fig. 3). Aa in Fig. 3 represents the mouse hippocampus CA3 region, and Ab represents the rat hippocampus neuron primary culture (20th  
10 day of culture). The symbols are as follows: SR, stratum radiatum; SL, stratum lucidum; SP, stratum pyramidale; and a bar, 30  $\mu$ m.

Furthermore, the neurons on the 22nd day in culture were stained with an anti-rabconnectin-3 $\beta$ -1 antibody (B in  
15 Fig. 3). In B of Fig. 3, a bar represents 200 nm. This result showed that rabconnectin-3 $\beta$  is associated with synaptic vesicles (B in Fig. 3).

These results show that rabconnectin-3 $\beta$  and rabconnectin-3 $\alpha$  colocalized on synaptic vesicles. The  
20 results shown in Fig. 3 are representative of three independent experiments.

#### (5) Study of binding of rabconnectin-3 $\alpha$ , Rab3 GEP, and Rab3 GAP to rabconnectin-3 $\beta$

25 The binding of rabconnectin-3 $\beta$  and rabconnectin-3 $\alpha$  was studied. An extract of a CSV fraction was immunoprecipitated by an anti-rabconnectin-3 $\alpha$  or 3 $\beta$ -2 antibody. Each immunoprecipitate was subjected to SDS-PAGE (8% polyacrylamide gel), followed by Western blotting with

the anti-rabconnectin-3 $\alpha$  or 3 $\beta$ -1 antibody. Furthermore, the immunoprecipitate by the anti-rabconnectin-3 $\beta$ -2 antibody was first washed with 0.5 M NaCl or 1% CHAPS, and then subjected to SDS-PAGE (8% polyacrylamide gel), followed by protein staining with Coomassie brilliant blue. Aa to Ac in Fig. 4 show the results. Aa is a result of the immunoprecipitate by the anti-rabconnectin-3 $\alpha$  antibody; Ab is a result of the immunoprecipitate by the anti-rabconnectin-3 $\beta$ -2 antibody; and Ac is a result of the immunoprecipitate by the anti-rabconnectin-3 $\beta$ -2 antibody with the NaCl or CHAPS treatment.

When rabconnectin-3 $\alpha$  was immunoprecipitated by its antibody from the extract of the P2C fraction, rabconnectin-3 $\beta$  was coimmunoprecipitated as expected from Western blotting (Aa in Fig. 4). Conversely, when rabconnectin-3 $\beta$  was immunoprecipitated by its antibody from the extract of the P2C fraction, rabconnectin-3 $\alpha$  was coimmunoprecipitated (Ab in Fig. 4). Rabconnectin-3 $\alpha$  and rabconnectin-3 $\beta$  coimmunoprecipitated using the anti-rabconnectin-3 $\beta$ -2 antibody were washed with either 0.5 M NaCl or 1% CHAPS, and subjected to protein staining with Coomassie brilliant blue. Both the proteins were not dissociated from each other, and stained in an apparently similar molecular ratio (Ac in Fig. 4). Rabconnectin-3 $\alpha$  and rabconnectin-3 $\beta$  were dissociated partly with 1 M NaCl and completely with 1% deoxycholate (data not shown). These results indicate that rabconnectin-3 $\alpha$  and rabconnectin-3 $\beta$  form a complex.

Next, it was examined which protein, rabconnectin-3 $\alpha$

or 3 $\beta$  bound Rab3 GEP and Rab3 GAP. For this purpose, pure samples of rabconnectin-3 $\beta$  and Rab3 GEP from insect cells and non-catalytic subunits of Rab3 GAP (p150) from *E. coli* were prepared (see J. Biol. Chem., 272, 3875-3878 (1997), J. Biol. Chem., 273, 24781-24785). As rabconnectin-3 $\alpha$  is a huge protein, its full-length protein has not been expressed in a mammalian cell line such as COS7 cells, and its pure recombinant sample has not been prepared from *E. coli* or insect cells. Therefore, native rabconnectin-3 $\alpha$ , and a complex of rabconnectin-3 $\alpha$  and -3 $\beta$  were prepared from the P2C fraction of rat brain. The complex of rabconnectin-3 $\alpha$  and -3 $\beta$  was immunoprecipitated from a P2C fraction, by an anti-rabconnectin-3 $\beta$ -2 antibody bound to protein A Sepharose beads, followed by washing the beads with 0.5 M NaCl. This sample was used as the complex of rabconnectin-3 $\alpha$  and -3 $\beta$ . In another experiment for preparing a chain, the complex of rabconnectin-3 $\alpha$  and -3 $\beta$  immunoprecipitated from the P2C fraction by the anti-rabconnectin-3 $\beta$ -2 antibody bound to the protein A Sepharose beads was washed with 1 M NaCl to dissociate rabconnectin-3 $\alpha$  from rabconnectin-3 $\beta$ . Rabconnectin-3 $\alpha$  dissociated from the beads was immunoprecipitated by an anti-rabconnectin-3 $\alpha$  antibody immobilized to the protein A Sepharose beads.

Affinity beads coupled with rabconnectin-3 $\beta$ , -3 $\alpha$ , or a complex thereof were prepared. For the rabconnectin-3 $\beta$ -coupled beads, a baculovirus bearing a rabconnectin-3 $\beta$  cDNA was prepared with pFastBac HTa rabconnectin-3 $\beta$  according to a manufacturer's protocol (GIBCO BRL), High Five cells (Invitrogen) were transfected with the baculovirus. The

extract of cells (5 mg protein) was prepared with Buffer A, and incubated overnight at 4°C with an anti-rabconnectin-3 $\beta$ -2 antibody immobilized on protein A Sepharose beads (20  $\mu$ l wet volume). For the rabconnectin-3 $\alpha$ -coupled beads, a  
5 complex of rabconnectin-3 $\alpha$  and -3 $\beta$  was first immunoprecipitated from the above P2C fraction, by the anti-rabconnectin-3 $\beta$ -2 antibody coupled with the protein A Sepharose beads. Rabconnectin-3 $\alpha$  was then dissociated from the beads by washing at 4°C for one hour with Buffer A  
10 containing 1 M NaCl. The dissociated rabconnectin-3 $\alpha$  (0.4  $\mu$ g protein) was collected, and incubated at 4°C overnight with the anti-rabconnectin-3 $\alpha$  antibody immobilized on the protein A Sepharose beads (20  $\mu$ l wet volume). For the complex-coupled beads, a complex of rabconnectin-3 $\alpha$  and -3 $\beta$   
15 was similarly immunoprecipitated from the P2C fraction, followed by washing the beads with Buffer A containing 0.5 M NaCl. The affinity beads coupled with rabconnectin 3 $\alpha$ , 3 $\beta$ , or a complex thereof were washed extensively with Buffer A.

20        Recombinant Rab3 GEP or GAP p150 was incubated with the protein A Sepharose beads coupled with recombinant rabconnectin 3 $\beta$  or native rabconnectin-3 $\alpha$ . On the other hand, after rabconnectin-3 $\alpha$  and -3 $\beta$  were immunoprecipitated from the P2C fraction, by the anti-rabconnectin-3 $\beta$ -2  
25 antibody immobilized on the beads, followed by washing the beads with 0.5 M NaCl, Rab3 GEP or GAP p150 was incubated with the beads. After the incubation, they were subjected to SDS-PAGE (8% polyacrylamide gel), followed by protein staining with Coomassie brilliant blue or Western blotting

with anti-Rab3 GEP or GAP p150 antibody. Ba1 to Bb2 in Fig. 4 show the results. Ba shows rabconnectin-3 $\alpha$ -coupled beads, Bb shows rabconnectin-3 $\beta$ -coupled beads, 1 represents Rab3 GEP, and 2 represents Rab3 GAP p150.

5       As a result, rabconnectin-3 $\beta$  bound recombinant Rab3 GEP stoichiometrically, whereas rabconnectin-3 $\alpha$  did not (Ba1 and Bb1 in Fig. 4). The complex directly bound Rab3 GEP; but stoichiometry of this binding was much less than that of rabconnectin-3 $\beta$  (data now shown). On the other hand,  
10 none of rabconnectin-3 $\alpha$ , -3 $\beta$ , and a complex thereof bound Rab3 GAP (Ba2, Bb2 in Fig. 4 (data regarding a complex are not shown)).

      The extract of the CSV fraction was immunoprecipitated by an anti-Rab3 GEP or GAP p150 antibody.  
15 Each immunoprecipitate was subjected to SDS-PAGE (8% polyacrylamide gel), followed by Western blotting with anti-Rab3 GEP or GAP p150 antibody and anti-rabconnectin-3 $\alpha$  antibody and an anti-rabconnectin-3 $\beta$ -1 antibody. Ca and Cb in Fig. 4 show the results. Ca represents the result of an  
20 immunoprecipitate by the anti-Rab3 GEP antibody, and Cb represents the result of an immunoprecipitate by the anti-Rab3 GAP p150 antibody.

      Consistently, rabconnectin-3 $\beta$  was coimmunoprecipitated from the extract of the P2C fraction,  
25 with Rab3 GEP or Rab3 GAP p150, by an anti-Rab3 GEP or anti-Rab3 GAP p150 antibody, in the same way as in rabconnectin-3 $\alpha$ . (see Ca and Cb in Fig. 4, and A in Fig. 1)

      Taken together, the above-mentioned results indicate that rabconnectin-3 $\beta$  directly binds Rab3 GEP, and

indirectly binds Rab3 GAP through an unidentified molecule under regulated manners. The results in Fig. 4 are representative of three independent experiments.

The anti-Rab3 GAP p150 antibody, the anti-Rab3 GEP  
5 antibody, and the anti-rabconnectin-3 $\alpha$  antibody used in Example 1 are a mouse monoclonal anti-Rab3 GAP p150 antibody, a rabbit polyclonal anti-Rab3 GEP antibody, and a rat polyclonal anti-rabconnectin-3 $\alpha$  antibody, prepared by methods described in J. Biol. Chem., 277, 9629-9632 (2002),  
10 J. Biol. Chem., 273, 24781-24785 (1998), and J. Biol. Chem., 273, 34580-34585 (1998). J. Biol. Chem., 277, 9629-9632 (2002) shows that rabconnectin-3 $\alpha$  is coimmunoprecipitated from the CSV fraction with Rab3 GEP or GAP by an anti-Rab3 GEP antibody or a Rab3 GAP p150 antibody, respectively.

15

#### Example 2

Neuroblastoma cells PC-12 ( $1 \times 10^6$ ) were cultured in a well coated with poly-L-lysine. On the following day of the culture starting day, pCMV myc expressing myc and pCMV  
20 myc:p160 expressing P160 (rabconnectin-3 $\beta$ ) as a fusion protein with myc were transfected to the cells by a lipofectin method. pCMV myc is described in J. Biol. Chem, 272, 11943-11951 (1997). pCMV myc:p160 integrates a DNA encoding an amino acid numbers 1 to 1490 (full length) of  
25 rabconnectin-3 $\beta$  so that a fusion protein of rabconnectin-3 $\beta$  and myc is expressed.

Two days after the transfection, a low-potassium (potassium concentration: 4.7 mM) buffer was added to the wells, followed by incubation at 37°C for 10 minutes. Then,



the buffer was removed, and a low-potassium or high-potassium (potassium concentration: 60 mM) buffer was added to the wells, followed by incubation at 37°C for 10 minutes. Thereafter, the amounts of growth hormones (GH) secreted to the supernatant and GH remaining in the cells were measured by a hGH ELISA kit (Roche Co.). The results were represented as a ratio (%) of secreted GH, with the total amount of GH in the supernatant and the cells being 100%.

Consequently, the growth hormones were released only in an amount of 2.3% of the total amount with the low-potassium buffer, whereas the growth hormones were released in an amount of 8.9% of the total amount with the high-potassium buffer. The release of the growth hormones increased by the stimulation of potassium was suppressed to 7.0% by the expression of p160. From these results, it is considered that p160 participates in the regulation of the transportation of synaptic vesicles such as the release of the growth hormones.